# Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Source: https://onco.cc/trials/nct04634877/  
OnCo record `nct04634877` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab, Carboplatin, Docetaxel and Cisplatin in endometrial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) is a phase 3 interventional study registered as NCT04634877 by Merck Sharp & Dohme LLC, with 990 participants enrolled, started 2021-01-10 and due to reach its primary completion in 2026-09-15. Interventions recorded: Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel and Cisplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04634877
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 990

## Sources

- ClinicalTrials.gov NCT04634877: https://clinicaltrials.gov/study/NCT04634877

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04634877.json